WST on XNYS, Health Care, West Pharmaceutical Services, Inc., job postings
Measures activity, not value. Not investment advice.
Net profit rose 30% to $638.9M and the stock is up 51% in 12 months.
GoodInstitutional holders rose 6.7% to 865 from 811 the quarter before
WatchCapital spending fell 38% to $39.1M in the latest quarter
Written by AI from the data on this page, 21 Nov 2026. Not investment advice.
Profile and fundamentals
From its SEC filings, 12 months to 30 Sep 2026
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
Industry
Surgical & medical instruments & apparatus (Health Care)
expected around 11 Feb 2027 (an estimate: a year ago it reported on 12 Feb 2026)
Revenue and net income per quarter. Quarter to 30 Sep 2026: revenue $874.5M, net income $214.0M.
31 Dec 2021RevenueNet incometallest bar $874.5M30 Sep 2026
See the numbers
Quarter to
Revenue
Net income
30 Sep 2026
$874.5M
$214.0M
30 Jun 2026
$872.3M
$154.0M
31 Mar 2026
$844.9M
$138.8M
31 Dec 2025
$805.0M
$132.1M
30 Sep 2025
$804.6M
$140.0M
30 Jun 2025
$766.5M
$131.8M
31 Mar 2025
$698.0M
$89.8M
31 Dec 2024
$748.8M
$130.1M
30 Sep 2024
$746.9M
$136.0M
30 Jun 2024
$702.1M
$111.3M
31 Mar 2024
$695.4M
$115.3M
31 Dec 2023
$732.0M
$137.0M
30 Sep 2023
$747.4M
$161.3M
30 Jun 2023
$753.8M
$155.1M
31 Mar 2023
$716.6M
$140.0M
31 Dec 2022
$708.7M
$103.0M
30 Sep 2022
$686.9M
$120.6M
30 Jun 2022
$771.3M
$188.5M
31 Mar 2022
$720.0M
$173.8M
31 Dec 2021
$730.8M
$147.7M
Fundamentals, 12 months to 30 Sep 2026
Measure
Latest
Year before
Peer median
RevenueiSales over the last 12 months reported.
$3.4B
$3.0B
Revenue growthiRevenue of the last 12 months compared with the 12 months before.
+13%
+13%
Net incomeiProfit after all costs and taxes over the last 12 months reported. Negative is a loss.
$638.9M
$491.7M
EPS (diluted)iEarnings per share: net income divided by the shares, counting options and convertibles. Left blank when the figures as filed do not fit today's share count (after a split).
$8.91
$6.75
Gross marginiWhat is left of each dollar of sales after the direct cost of making the product or service.
37.6%
35.6%
60.5%
Operating marginiOperating income as a share of sales: profit from the business before interest and taxes.
23.0%
19.5%
-8.3%
Net marginiNet income as a share of sales: what the owners keep of each dollar sold.
18.8%
16.3%
-10.1%
Return on equityiNet income of the last 12 months divided by shareholders' equity (the average of the latest balance sheet and the one a year earlier): the profit made on the owners' money.
21.2%
-26.3%
Free cash flowiCash from operations minus capital spending over the last 12 months: cash the business produced.
$453.4M
$379.1M
CashiCash, cash equivalents and short-term investments on the latest balance sheet.
$464.1M
$628.5M
DebtiShort- and long-term borrowings on the latest balance sheet. Operating leases are not counted.
$202.9M
$202.7M
Net debtiDebt minus cash. Negative means the company holds more cash than it owes (net cash).
-$261.2M (net cash)
-$425.8M
Debt to equityiDebt divided by shareholders' equity on the latest balance sheet: how much is borrowed for each dollar the owners have in the company. Blank when equity is negative.
0.07
0.31
Book value per shareiShareholders' equity (assets minus liabilities) on the latest balance sheet divided by the shares outstanding.
$42.61
P/EiPrice to earnings: market cap divided by net income of the last 12 months. What investors pay for one dollar of yearly profit. Blank when the company made a loss.
42.6
28.0
P/SiPrice to sales: market cap divided by revenue of the last 12 months.
8.0
2.3
EV/SalesiEnterprise value (market cap plus debt minus cash) divided by revenue of the last 12 months.
7.9
2.5
P/BiPrice to book: market cap divided by shareholders' equity on the latest balance sheet. Blank when equity is negative.
9.2
2.8
Dividend yieldiDividends per share declared in the latest fiscal year divided by the share price.
0.22%
1.4%
Latest = 12 months to 30 Sep 2026; balance-sheet lines at its end. Peer median: companies in the same industry (SIC code), or the sector when the industry is small.
Peers nearest by market cap, its own industry first
Revenue growth iSales in the latest reported quarter compared with the same quarter a year earlier.
+8.7%
$874.5M vs $804.6M (quarter ended 30 Sep 2026)
Capital spending iMoney spent on buildings, machines and equipment in the latest quarter, compared with the same quarter a year earlier.
-38%
$39.1M vs $63.3M (quarter ended 30 Sep 2026)
Insider buy/sell iShares the company's insiders (directors, officers and owners of 10% or more) bought minus what they sold on the open market in the last 90 days, from their Form 4 filings.
-$5.4M
bought $0, sold $5.4M
Institutional holders iThe number of institutional investment managers (13F filers: funds, pensions, asset managers) reporting the stock, compared with the quarter before. 13F reports are public 45 days after quarter end and show long positions only.
+6.7%
865 13F filers vs 811
Institutional ownership iShares held by 13F filers at the latest quarter end, divided by the shares outstanding in the company's latest filing. Above 100% usually means a stale share count or double counting, and is marked.
99%
68.7M shares held by 13F filers (30 Sep 2026) of 69.7M outstanding (21 Oct 2026)
Short interest iShares sold short and not yet bought back, divided by the shares outstanding in the company's latest filing. From FINRA's latest short interest report: FINRA reports twice a month and publishes 7 business days after the settlement date. Above 100% means a stale share count, and is marked.
2.6%
1.8M shares sold short (30 Oct 2026) of 69.7M outstanding (21 Oct 2026)
Days to cover iShort interest divided by the stock's average daily trading volume, as FINRA publishes it: how many days of normal trading it would take short sellers to buy back every share. Latest report.
2.3
1.8M shares sold short (30 Oct 2026) divided by the stock's average daily volume, as FINRA publishes it
Short interest change iHow the number of shares sold short changed between FINRA's two latest reports, about two weeks apart.
-10%
2.0M shares sold short in the report before, 1.8M on 30 Oct 2026
Short sale volume iShare of the stock's latest daily volume on FINRA-reported off-exchange venues that was sold short. Market makers sell short routinely, so 40% to 50% is normal; compare it with the company's own 1-year average in the cell's details. A daily flow, not short interest.
48%
48% of off-exchange volume on 20 Nov 2026 was short sales; 1-year average 53%
Visa hiring (foreign workers) iApplications to hire foreign specialists on H-1B and E-3 visas certified by the Labor Department in the last 12 months, compared with the 12 months before. This is NOT total hiring: most hires need no visa. Open jobs shows total hiring where we track it.
+21%
17 vs 14 applications
Lobbying iWhat the company reported spending on federal lobbying over the last four quarters.
$170K
4 quarters
News iArticles about the company published in the last 7 days, from our Google News collection (one search per company, every half hour). Blank when we do not collect news for this company.
35
35 articles in the last 7 days; its usual week has 5.5 (the median of the 26 weeks before).
News vs usual iArticles in the last 7 days divided by the company's usual week: the median week of the 26 weeks before. Blank when the usual week has fewer than one article.
6.4×
35 articles in the last 7 days; its usual week has 5.5.
Price $390.30 on 20 Nov 2026, +51% over 12 months (12-month range $230.95 to $417.80)
Sharp change
8-K and other filings
Lobbying filing
Insider net buying (open market). Insiders sold a net $6.6M in the last 12 months (the 12 months before: $0).H-1B/E-3 applications certified. H-1B/E-3 applications certified: 17 published in the last 12 months, +21% on the 12 months before.Revenue per quarter. Revenue $874.5M in the latest quarter, +8.7% on a year earlier.Capital spending per quarter. Capital spending $39.1M in the latest quarter, -38% on a year earlier.Institutional holders (13F filers). 865 13F filers reported holding it in the latest 13F quarter, +21% on a year earlier.Lobbying spend. Lobbying spend: $170K published in the last 12 months, +13% on the 12 months before.
Every point sits on the day the fact became public (filing acceptance or publication), not the day it happened; prices through 20 Nov 2026. Hover or tap a marker for the fact; click it for the evidence or the source. No data here for: federal obligations, workers in warn layoff notices.
Quarter ended 31 Dec 2021: $730.8M, +26% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $720.0M, +7.4% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $771.3M, +6.6% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $686.9M, -2.8% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $708.7M, -3.0% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $716.6M, -0.5% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $753.8M, -2.3% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $747.4M, +8.8% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $732.0M, +3.3% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $695.4M, -3.0% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $702.1M, -6.9% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $746.9M, -0.1% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $748.8M, +2.3% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $698.0M, +0.4% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $766.5M, +9.2% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $804.6M, +7.7% on a year earlier; public on 24 Oct 2025
Quarter ended 31 Dec 2025: $805.0M, +7.5% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $844.9M, +21% on a year earlier; public on 24 Apr 2026
Quarter ended 30 Jun 2026: $872.3M, +14% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $874.5M, +8.7% on a year earlier; public on 30 Oct 2026
Capital spending per quarter
Quarter ended 31 Dec 2021: $76.5M, +33% on a year earlier; public on 23 Feb 2022
Quarter ended 31 Mar 2022: $65.8M, +20% on a year earlier; public on 29 Apr 2022
Quarter ended 30 Jun 2022: $66.1M, +16% on a year earlier; public on 29 Jul 2022
Quarter ended 30 Sep 2022: $57.8M, -11% on a year earlier; public on 28 Oct 2022
Quarter ended 31 Dec 2022: $94.9M, +24% on a year earlier; public on 22 Feb 2023
Quarter ended 31 Mar 2023: $82.1M, +25% on a year earlier; public on 28 Apr 2023
Quarter ended 30 Jun 2023: $75.4M, +14% on a year earlier; public on 28 Jul 2023
Quarter ended 30 Sep 2023: $95.8M, +66% on a year earlier; public on 27 Oct 2023
Quarter ended 31 Dec 2023: $108.7M, +15% on a year earlier; public on 21 Feb 2024
Quarter ended 31 Mar 2024: $90.6M, +10% on a year earlier; public on 26 Apr 2024
Quarter ended 30 Jun 2024: $100.2M, +33% on a year earlier; public on 26 Jul 2024
Quarter ended 30 Sep 2024: $81.3M, -15% on a year earlier; public on 25 Oct 2024
Quarter ended 31 Dec 2024: $104.9M, -3.5% on a year earlier; public on 19 Feb 2025
Quarter ended 31 Mar 2025: $71.3M, -21% on a year earlier; public on 25 Apr 2025
Quarter ended 30 Jun 2025: $75.2M, -25% on a year earlier; public on 25 Jul 2025
Quarter ended 30 Sep 2025: $63.3M, -22% on a year earlier; public on 24 Oct 2025
Quarter ended 31 Dec 2025: $76.1M, -27% on a year earlier; public on 18 Feb 2026
Quarter ended 31 Mar 2026: $42.7M, -40% on a year earlier; public on 24 Apr 2026
Quarter ended 30 Jun 2026: $43.2M, -43% on a year earlier; public on 24 Jul 2026
Quarter ended 30 Sep 2026: $39.1M, -38% on a year earlier; public on 30 Oct 2026
Institutional holders (13F filers)
31 Dec 2021 report: 644; public on 14 Feb 2022
31 Mar 2022 report: 664; public on 16 May 2022
30 Jun 2022 report: 607; public on 15 Aug 2022
30 Sep 2022 report: 576; public on 14 Nov 2022
31 Dec 2022 report: 574; public on 14 Feb 2023
31 Mar 2023 report: 637; public on 15 May 2023
30 Jun 2023 report: 666; public on 14 Aug 2023
30 Sep 2023 report: 696; public on 14 Nov 2023
31 Dec 2023 report: 725; public on 14 Feb 2024
31 Mar 2024 report: 738; public on 15 May 2024
30 Jun 2024 report: 735; public on 14 Aug 2024
30 Sep 2024 report: 682; public on 14 Nov 2024
31 Dec 2024 report: 707; public on 14 Feb 2025
31 Mar 2025 report: 680; public on 15 May 2025
30 Jun 2025 report: 697; public on 14 Aug 2025
30 Sep 2025 report: 716; public on 14 Nov 2025
31 Dec 2025 report: 770; public on 17 Feb 2026
31 Mar 2026 report: 738; public on 15 May 2026
30 Jun 2026 report: 811; public on 14 Aug 2026
30 Sep 2026 report: 865; public on 16 Nov 2026
Lobbying spend
Quarter from 1 Apr 2025: $50K published
Quarter from 1 Jul 2025: $50K published
Quarter from 1 Oct 2025: $50K published
Quarter from 1 Jan 2026: $50K published
Quarter from 1 Apr 2026: $50K published
Quarter from 1 Jul 2026: $50K published
Quarter from 1 Oct 2026: $20K published
What is unusual now
Nothing unusual in the last 90 days: no change appeared. Its most unusual measure now is capital expenditure, quarter at $39.1M (30 Sep 2026), 47% below its normal quarter of $73.2M; higher than 59% of its own history.
In 12 months: 2 director or officer changes, 2 major agreements, 1 cybersecurity incident, 1 agreement ended. Results releases and routine reports are left out.
Filed
What happened
Source
26 Oct 2026
Signed a major agreement; A major agreement endedSame filing: took on new debt
Reported lobbying spend: $20K in Q3 2026, $50K in Q2 2026. Rows are lobbying firms hired or let go; amounts are reported per quarter, not per firm here.
Date
Change
Lobbying firm
Issue
Source
31 Jul 2026
Ended
Clark Hill Public Strategies LLCfor West Pharmaceutical Services, Inc.
Matters relating to the pharmaceutical manufacturing and supply chain security.MED, TAR, Trade
Two or more unrelated kinds of records unusual within 30 days
1 Jun 2021confirmed
Confirmed across sources Filings + Financials and Short interest and volume
West Pharmaceutical Services(WST): reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year, while it had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year. Two unrelated kinds of activity within 91 days.
Financials: Quarterly capital spending jump, became public on 4 May 2021
Financials: Quarterly revenue change, became public on 4 May 2021
Short interest and volume: Short interest spike, became public on 26 May 2021
Short interest and volume: Short interest spike, became public on 10 Jun 2021
Short interest and volume: Short interest spike, became public on 26 Jun 2021
Short interest and volume: Short interest spike, became public on 13 Jul 2021
Financials: Quarterly revenue change, became public on 3 Aug 2021
The quarter ended 31 Mar 2021 against the 8 quarters before it.
this quarterearliernormal: $481.1MSee the evidence (7 changes)
Financials: Quarterly capital spending jump became public on 4 May 2021
West Pharmaceutical Services spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.
This period
$54.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$34.6M
Typical spread (median absolute deviation)
$4.4M
How far from its usual level
+3.1
Same quarter last year
$32.1M
History used
4,200 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 4 May 2021
West Pharmaceutical Services reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.
This period
$670.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$481.1M
Typical spread (median absolute deviation)
$31.2M
How far from its usual level
+3.9
Same quarter last year
$491.5M
History used
4,292 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 May 2021
West Pharmaceutical Services had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.
This period
1.0M (the 14 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
50K
How far from its usual level
+4.3
Same report last year
726K
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2021
West Pharmaceutical Services had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.
This period
1.0M (the 28 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
57K
How far from its usual level
+3.7
Same report last year
701K
History used
1,246 days
the 28 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2021
West Pharmaceutical Services had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.
This period
1.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.5
Same report last year
914K
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jul 2021
West Pharmaceutical Services had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.
This period
1.1M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.4
Same report last year
916K
History used
1,279 days
the 30 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 3 Aug 2021
West Pharmaceutical Services reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.
This period
$723.6M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$509.4M
Typical spread (median absolute deviation)
$39.2M
How far from its usual level
+3.7
Same quarter last year
$527.2M
History used
4,383 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
Timeline
Changes and notable records, by the date each became public
had 2.1M shares sold short in the 30 May 2025 report, 1.7× the same report last year.
Same report last year: 1.3M; its normal report is 1.4M.
See the evidence
This period
2.1M (the 30 May 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
144K
How far from its usual level
+3.5
Same report last year
1.3M
History used
2,709 days
the 30 May 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.2M shares sold short in the 15 May 2025 report, 2.0× the same report last year.
Same report last year: 1.1M; its normal report is 1.4M.
See the evidence
This period
2.2M (the 15 May 2025 report)
Normal report (median of 24 earlier)
1.4M
Typical spread (median absolute deviation)
137K
How far from its usual level
+4.4
Same report last year
1.1M
History used
2,694 days
the 15 May 2025 report24 earlier reportsnormal: 1.4M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 2.5M shares sold short in the 30 Apr 2025 report, 2.4× the same report last year.
Same report last year: 1.0M; its normal report is 1.3M.
See the evidence
This period
2.5M (the 30 Apr 2025 report)
Normal report (median of 24 earlier)
1.3M
Typical spread (median absolute deviation)
125K
How far from its usual level
+6.5
Same report last year
1.0M
History used
2,679 days
the 30 Apr 2025 report24 earlier reportsnormal: 1.3M
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
spent $95.8M on capital projects in the quarter ended 30 Sep 2023, 1.7× the same quarter last year.
Same quarter last year: $57.8M; its normal quarter is $70.8M.
See the evidence
This period
$95.8M (the quarter ended 30 Sep 2023)
Normal quarter (median of 8 earlier)
$70.8M
Typical spread (median absolute deviation)
$5.6M
How far from its usual level
+3.0
Same quarter last year
$57.8M
History used
5,113 days
the quarter ended 30 Sep 20238 earlier quartersnormal: $70.8M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
saw 103 13F filers open a new position in the quarter ended 31 Mar 2023, 1.8× the same quarter last year.
Same quarter last year: 56; its normal quarter is 60.
See the evidence
This period
103 (the quarter ended 31 Mar 2023)
Normal quarter (median of 8 earlier)
60
Typical spread (median absolute deviation)
8
How far from its usual level
+3.6
Same quarter last year
56
History used
3,469 days
the quarter ended 31 Mar 20238 earlier quartersnormal: 60
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 6+ earlier periods, 730+ days of history and a value of at least 20.
reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.
Same quarter last year: $527.2M; its normal quarter is $509.4M.
See the evidence
This period
$723.6M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$509.4M
Typical spread (median absolute deviation)
$39.2M
How far from its usual level
+3.7
Same quarter last year
$527.2M
History used
4,383 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.
Same report last year: 916K; its normal report is 699K.
See the evidence
This period
1.1M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.4
Same report last year
916K
History used
1,279 days
the 30 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.
Same report last year: 914K; its normal report is 699K.
See the evidence
This period
1.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.5
Same report last year
914K
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.
Same report last year: 701K; its normal report is 699K.
See the evidence
This period
1.0M (the 28 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
57K
How far from its usual level
+3.7
Same report last year
701K
History used
1,246 days
the 28 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year, while it had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year. Two unrelated kinds of activity within 91 days.
See the evidence (7 changes)
Financials: Quarterly capital spending jump became public on 4 May 2021
West Pharmaceutical Services spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.
This period
$54.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$34.6M
Typical spread (median absolute deviation)
$4.4M
How far from its usual level
+3.1
Same quarter last year
$32.1M
History used
4,200 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Financials: Quarterly revenue change became public on 4 May 2021
West Pharmaceutical Services reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.
This period
$670.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$481.1M
Typical spread (median absolute deviation)
$31.2M
How far from its usual level
+3.9
Same quarter last year
$491.5M
History used
4,292 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Short interest and volume: Short interest spike became public on 26 May 2021
West Pharmaceutical Services had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.
This period
1.0M (the 14 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
50K
How far from its usual level
+4.3
Same report last year
726K
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 10 Jun 2021
West Pharmaceutical Services had 1.0M shares sold short in the 28 May 2021 report, 1.4× the same report last year.
This period
1.0M (the 28 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
57K
How far from its usual level
+3.7
Same report last year
701K
History used
1,246 days
the 28 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 26 Jun 2021
West Pharmaceutical Services had 1.1M shares sold short in the 15 Jun 2021 report, 1.2× the same report last year.
This period
1.1M (the 15 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.5
Same report last year
914K
History used
1,264 days
the 15 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Short interest and volume: Short interest spike became public on 13 Jul 2021
West Pharmaceutical Services had 1.1M shares sold short in the 30 Jun 2021 report, 1.2× the same report last year.
This period
1.1M (the 30 Jun 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
65K
How far from its usual level
+4.4
Same report last year
916K
History used
1,279 days
the 30 Jun 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
Financials: Quarterly revenue change became public on 3 Aug 2021
West Pharmaceutical Services reported revenue of $723.6M for the quarter ended 30 Jun 2021, 1.4× the same quarter last year.
This period
$723.6M (the quarter ended 30 Jun 2021)
Normal quarter (median of 8 earlier)
$509.4M
Typical spread (median absolute deviation)
$39.2M
How far from its usual level
+3.7
Same quarter last year
$527.2M
History used
4,383 days
the quarter ended 30 Jun 20218 earlier quartersnormal: $509.4M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
Several things at once means two or more unrelated kinds of records changed sharply within 30 days. Records that come from the same documents (for example filings and the financials taken from them) count as one kind.
26 May 2021Short interest and volume change
had 1.0M shares sold short in the 14 May 2021 report, 1.4× the same report last year.
Same report last year: 726K; its normal report is 699K.
See the evidence
This period
1.0M (the 14 May 2021 report)
Normal report (median of 24 earlier)
699K
Typical spread (median absolute deviation)
50K
How far from its usual level
+4.3
Same report last year
726K
History used
1,232 days
the 14 May 2021 report24 earlier reportsnormal: 699K
Fires when the period is at least 3.5 robust standard deviations above the company's own median, with 18+ earlier periods, 365+ days of history and a value of at least 500K.
reported revenue of $670.7M for the quarter ended 31 Mar 2021, 1.4× the same quarter last year.
Same quarter last year: $491.5M; its normal quarter is $481.1M.
See the evidence
This period
$670.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$481.1M
Typical spread (median absolute deviation)
$31.2M
How far from its usual level
+3.9
Same quarter last year
$491.5M
History used
4,292 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $481.1M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $10.0M.
spent $54.7M on capital projects in the quarter ended 31 Mar 2021, 1.7× the same quarter last year.
Same quarter last year: $32.1M; its normal quarter is $34.6M.
See the evidence
This period
$54.7M (the quarter ended 31 Mar 2021)
Normal quarter (median of 8 earlier)
$34.6M
Typical spread (median absolute deviation)
$4.4M
How far from its usual level
+3.1
Same quarter last year
$32.1M
History used
4,200 days
the quarter ended 31 Mar 20218 earlier quartersnormal: $34.6M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
spent $57.7M on capital projects in the quarter ended 31 Dec 2020, 1.5× the same quarter last year.
Same quarter last year: $37.6M; its normal quarter is $31.9M.
See the evidence
This period
$57.7M (the quarter ended 31 Dec 2020)
Normal quarter (median of 8 earlier)
$31.9M
Typical spread (median absolute deviation)
$3.4M
How far from its usual level
+5.2
Same quarter last year
$37.6M
History used
4,110 days
the quarter ended 31 Dec 20208 earlier quartersnormal: $31.9M
Fires when the period is at least 3.0 robust standard deviations above the company's own median, with 6+ earlier periods, 540+ days of history and a value of at least $5.0M.
Fires on an 8-K with item 5.02 after 90 days without one.
Showing the newest 40 of 69 entries; narrow the window or the kind of data to see older ones.
Not listed: 174 routine records (quarterly and annual reports, results releases, other 8-K items, material agreements and individual insider sales), counted over all history.
Identifiers and sources
How records are matched to this company, and what each source holds for it
Cik
0000105770
Ticker
WST
Domain
westpharma.com
Employer name
West Corporation, West Pharmaceutical Services, Inc. (2 unverified)
Hq location
PA|EXTON|19341 (1 unverified)
Lobbying client
west pharmaceutical services
Name
Tech Group Europe Limited, Tech Group Grand Rapids, Inc, TGPR Holdings Limited, WEST CO INC and 38 more
Uei
JP72MQBU2RJ4
Wikidata
Q124358903
DOL H-1B labor condition applications and PERM certifications524 data points20 Jan 2020 to 31 Aug 2026
Federal lobbying disclosures (LDA)4 records, 30 data points1 Jun 2020 to 30 Sep 2026
SEC Form 13F institutional holdings1 record, 481 data points30 Jun 2013 to 30 Sep 2026
SEC EDGAR filings (8-K items, S-1, Form D, 10-K/10-Q)141 records18 Feb 2016 to 29 Oct 2026
SEC XBRL company facts (revenue, capex, R&D, backlog...)1347 data points31 Dec 2007 to 21 Oct 2026
SEC Form 4 insider transactions70 records, 228 data points24 Feb 2016 to 15 Sep 2026
FINRA short interest (twice monthly)627 data points29 Dec 2017 to 30 Oct 2026
FINRA daily short sale volume (off-exchange)4178 data points1 Aug 2018 to 20 Nov 2026
USASpending.gov federal awards1 record, 75 data points4 Dec 2007 to 1 Feb 2021
WARN layoff notices (state labor agencies)1 record, 3 data points5 Oct 2009 to 8 Oct 2009